Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 6/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.43 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.43 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.43 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.43 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.43 |
| ▸ | CDK1 | P06493 | 2/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.43 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.43 |
| ▸ | MAP2 | P11137 | 1/20 | 0.42 |
| ▸ | CETP | P11597 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5161736 | 0.88 | CYP2C9 (0.71) | CYP2C9CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL7487055 | 0.87 | CYP2C9 (0.73) | CYP2C9CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL8482038 | 0.85 | CYP2C9 (0.68) | CYP2C9CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL5161705 | 0.85 | CYP2C9 (0.87) | CYP2C9CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL5157873 | 0.85 | CYP2C9 (0.68) | CYP2C9CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL5159266 | 0.84 | CYP2C9 (0.69) | CYP2C9CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL5415892 | 0.84 | CYP2C9 (0.71) | CYP2C9CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL5159446 | 0.83 | CYP2C9 (0.66) | CYP2C9CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL5417980 | 0.83 | CYP2C9 (0.66) | CYP2C9CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL5161367 | 0.83 | CYP2C9 (1.00) | CYP2C9CYP1A2CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7179920-B2 | 3-thia-4-arylquinolin-2-one derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-20 | — | — | US | claimed |
| US-20050080105-A1 | [4-(5-Chloro-2-hydroxy-phenyl)-2-oxo-6-trifluoromethyl- 1,2-dihydro-quinolin-3-ylsulfanyl]-acetic acid for example; potassium channel modulators for treating erectile dysfunction and irritable bowel syndrome | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-14 | — | — | US | claimed |
| US-7179920-B2 | 3-thia-4-arylquinolin-2-one derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179920-B2 | 3-thia-4-arylquinolin-2-one derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179920-B2 | 3-thia-4-arylquinolin-2-one derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-20 | — | — | US | disclosed |
| US-7049309-B2 | 3-Thia-4-arylquinolin-2-one potassium channel modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-23 | — | — | US | disclosed |
| US-7002015-B2 | 3-Thia-4-arylquinolin-2-one derivatives as smooth muscle relaxants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-21 | — | — | US | disclosed |
| US-20050176763-A1 | 3-Thia-4-arylquinolin-2-one potassium channel modulators | BRISTOL-MYERS SQUIBB COMPANY | 2005-08-11 | — | — | US | disclosed |
| US-20050096329-A1 | 3-Thia-4-arylquinolin-2-one derivatives as smooth muscle relaxants | BRISTOL-MYERS SQUIBB COMPANY | 2005-05-05 | — | — | US | disclosed |
| US-20050080105-A1 | [4-(5-Chloro-2-hydroxy-phenyl)-2-oxo-6-trifluoromethyl- 1,2-dihydro-quinolin-3-ylsulfanyl]-acetic acid for example; potassium channel modulators for treating erectile dysfunction and irritable bowel syndrome | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176763-A1 | 3-Thia-4-arylquinolin-2-one potassium channel modulators | KCNQ2, KCNJ2, KCNQ1 | CYP2C9 554/4885CYP1A2 281/4885CYP3A4 453/4885 |
| US-20050096329-A1 | 3-Thia-4-arylquinolin-2-one derivatives as smooth muscle relaxants | KCNQ2, KCNQ1, KCNQ5 | CYP2C9 604/4885CYP1A2 244/4885CYP3A4 457/4885 |
| US-20050080105-A1 | [4-(5-Chloro-2-hydroxy-phenyl)-2-oxo-6-trifluoromethyl- 1,2-dihydro-quinolin-3-ylsulfanyl]-acetic acid for example; potassium channel modulators for treating erectile dysfunction and irritable bowel syndrome | KCNJ2, KCNN2, KCNJ11 | CYP2C9 781/4885CYP1A2 258/4885CYP3A4 856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.